tiprankstipranks
Trending News
More News >
Ascelia Pharma AB (SE:ACE)
:ACE
Advertisement

Ascelia Pharma AB (ACE) AI Stock Analysis

Compare
1 Followers

Top Page

SE:ACE

Ascelia Pharma AB

(Berlin:ACE)

Rating:43Neutral
Price Target:
Ascelia Pharma AB's overall stock score reflects significant financial challenges due to zero revenue and consistent net losses, offset slightly by a strong cash position. Technical analysis indicates positive momentum, but the speculative nature of the stock, highlighted by a negative P/E ratio and lack of profitability, results in a low overall score. The stock remains highly speculative, hinging on future product development success.

Ascelia Pharma AB (ACE) vs. iShares MSCI Sweden ETF (EWD)

Ascelia Pharma AB Business Overview & Revenue Model

Company DescriptionAscelia Pharma AB (ACE) is a Swedish specialty pharmaceutical company focused on the development of novel drugs that address unmet medical needs, primarily in the field of oncology. The company's lead product candidate, Orviglance (formerly known as Mangoral), is an oral imaging drug designed to enhance the visualization of liver metastases in patients with impaired kidney function undergoing MRI scans. Ascelia Pharma operates within the pharmaceutical sector, with a commitment to improving diagnostic procedures and treatment options for cancer patients.
How the Company Makes MoneyAscelia Pharma AB generates revenue primarily through the research and development of its proprietary drug candidates. The company aims to monetize its products by progressing them through clinical trials and eventually bringing them to the market upon regulatory approval. Key revenue streams include potential licensing agreements, partnerships with larger pharmaceutical companies, and eventual sales of approved products. Additionally, Ascelia may receive milestone payments and royalties from collaborations with other entities in the pharmaceutical industry. The company's success in securing partnerships and advancing its drug candidates through the development pipeline is crucial to its financial performance.

Ascelia Pharma AB Financial Statement Overview

Summary
Ascelia Pharma AB exhibits a challenging financial position typical of early-stage biotech companies. The absence of revenue and persistent net losses, combined with a reliance on external financing, underscore the financial risks associated with the company's operations. However, a strong cash position offers some buffer against immediate liquidity concerns, though long-term sustainability hinges on successful product development and commercialization.
Income Statement
10
Very Negative
Ascelia Pharma AB has struggled to generate revenue over the past several years, with total revenue consistently at zero. Despite efforts to control costs, the company has reported significant net losses each year, indicative of its heavy R&D expenditure typical within the biotechnology industry. The absence of revenue and consistent negative net income results in extremely poor margins, reflecting a challenging financial position.
Balance Sheet
40
Negative
The balance sheet shows a moderately healthy equity position with a strong level of cash and cash equivalents. However, the company's debt-to-equity ratio has increased over time, reflecting a growing reliance on debt financing. The equity ratio remains stable but has slightly declined, indicating a gradual erosion of equity relative to assets.
Cash Flow
25
Negative
The company's operating cash flow is persistently negative, indicating significant cash burn which is common for biotech firms in development stages. Despite this, recent financing activities have provided substantial cash inflows, helping to offset the negative free cash flow. However, sustainable cash flow from operations remains a critical challenge.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-1.05M-3.89M-8.72M-825.00K
EBITDA-67.69M-108.56M-132.06M-128.42M-98.91M
Net Income-80.03M-109.29M-131.22M-125.90M-98.70M
Balance Sheet
Total Assets140.92M87.07M218.57M333.49M255.37M
Cash, Cash Equivalents and Short-Term Investments75.26M21.86M149.56M261.60M184.69M
Total Debt25.40M1.06M484.00K1.66M1.78M
Total Liabilities61.98M12.74M37.71M25.66M19.32M
Stockholders Equity78.94M74.33M180.86M307.83M236.06M
Cash Flow
Free Cash Flow-62.84M-126.79M-125.33M-116.60M-85.92M
Operating Cash Flow-62.84M-126.79M-125.26M-116.56M-85.53M
Investing Cash Flow0.0046.00K-65.00K-38.00K75.99M
Financing Cash Flow115.19M-936.00K-1.10K184.87M92.72M

Ascelia Pharma AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.68
Price Trends
50DMA
4.45
Positive
100DMA
3.81
Positive
200DMA
3.34
Positive
Market Momentum
MACD
0.13
Negative
RSI
55.70
Neutral
STOCH
52.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ACE, the sentiment is Positive. The current price of 4.68 is above the 20-day moving average (MA) of 4.56, above the 50-day MA of 4.45, and above the 200-day MA of 3.34, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 55.70 is Neutral, neither overbought nor oversold. The STOCH value of 52.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ACE.

Ascelia Pharma AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
kr493.24M-18.79%21.85%
58
Neutral
kr413.08M-47.73%45.52%93.35%
52
Neutral
kr6.05B8.94-59.74%2.10%25.95%22.55%
47
Neutral
kr130.55M-89.24%-17.91%22.80%
43
Neutral
kr544.74M-138.29%39.92%
43
Neutral
kr257.00M
5303.85%55.59%
36
Underperform
kr247.51M-54.29%-100.00%-17.35%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:ACE
Ascelia Pharma AB
4.70
1.95
70.79%
SE:IMMU
Immunicum AB
9.47
2.00
26.76%
SE:ISOFOL
Isofol Medical AB
0.88
-1.47
-62.49%
SE:NXTCL
NextCell Pharma AB
1.17
-0.24
-16.88%
SE:XBRANE
Xbrane Biopharma AB
0.27
0.10
59.17%
SE:XINT
Xintela AB
0.39
0.11
39.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025